Dracen Pharmaceuticals, Inc.

The biopharma IPO window is rewarding investors with rapid valuation step-ups and a shortened trajectory to an exit (some companies have gone public two to three years post-Series A). This path to liq

Derived from Strategic Transactions , Informa’s premium source for tracking life sciences deal activity, the Venture Funding Deals column provides a comprehensive monthly review of emerging bioph